Table of Contents: CATIE TreatmentUpdate - 2006

 TreatmentUpdate 157: August / September - Vol. 18, No. 4

EnglishFrançais 

  I ANTI-HIV AGENTS: A. Introduction

Selected highlights from the XVI International AIDS Conference, Toronto, Canada, 13-18 August 2006

I AGENTS ANTI-VIH : A. Introduction

Faits saillants sélectionnés du XVIe Congrès international sur le sida, Toronto, Canada, du 13 au 18 août 2006

I ANTI-HIV AGENTS: B. Darunavir shows its strength

The protease inhibitor darunavir (Prezista, TMC114) has recently been approved for use in Canada and the United States. Darunavir is supposed to be active against strains of HIV that are resistant to other protease inhibitors, so this drug is of particular interest to treatment-experienced PHAs.

I AGENTS ANTI-VIH : B. Le darunavir montre sa force

L’inhibiteur de la protéase darunavir (Prezista, TMC114) a récemment été approuvé au Canada et aux États-Unis. Ce médicament agirait contre des souches du VIH qui sont résistantes à d’autres inhibiteurs de la protéase, donc il suscite beaucoup d’intérêt chez les PVVIH ayant déjà reçu des traitements.

I ANTI-HIV AGENTS: C. Merck integrase inhibitor

Most licensed anti-HIV agents interfere with the ability of HIV-infected cells to replicate (make new copies of HIV). These drugs do so by blocking the activity of two enzymes—reverse transcriptase and protease. However, HIV has many other potential enzymes and proteins that can be attacked, such as the enzyme integrase.

I AGENTS ANTI-VIH : C. Merck met au point un inhibiteur de l’intégrase

La plupart des médicaments anti-VIH homologués empêchent les cellules infectées par le VIH de se répliquer (faire de nouvelles copies de VIH). Ces médicaments agissent en bloquant l’activité de deux enzymes : la transcriptase inverse et la protéase. Cependant, le VIH renferme plusieurs autres enzymes et protéines auxquelles on pourrait potentiellement s’attaquer, y compris l’enzyme intégrase.

I ANTI-HIV AGENTS: D. Access denied—keeping HIV out with entry inhibitors

Most currently available anti-HIV drugs work by interfering with HIV after it has infected a cell. However, several other drugs exert their anti-HIV activity by helping to keep HIV from entering a cell.

I AGENTS ANTI-VIH : D. L’accès refusé—les inhibiteurs de l’entrée empêchent le VIH de faire ses ravages

La plupart des médicaments anti-VIH actuellement sur le marché agissent contre le VIH après qu’il est entré dans une cellule. Or il existe maintenant plusieurs médicaments dont l’action anti-VIH consiste à empêcher le virus d’entrer dans la cellule.

I ANTI-HIV AGENTS: E. Maraviroc in treatment-experienced PHAs

Although maraviroc is supposed to work only against R5-tropic strains of HIV, it may still have some benefit in PHAs who have both X4- and R5-tropic strains. At least this was the theory underpinning the rationale for a study of maraviroc in participants who had the following:

I ANTI-HIV AGENTS: F. Vicriviroc: Is the risk of cancer increased?

Government-funded researchers in the United States conducted a study called ACTG 5211 to assess the preliminary effectiveness and safety of the CCR5 receptor blocker vicriviroc (VCV) over the course of one year.

II MENTAL HEALTH: A. Vancouver team uncovers self-medication with crystal meth

A major health issue for some people at risk for or who have HIV infection is substance use. This behaviour can lead to addiction and, in the long-term, reduce overall health as well as weaken the immune system. The following is a short list of some commonly used substances in high-income countries.

 TreatmentUpdate 156: June / July - Vol. 18, No. 3

English  Françias

A. Introduction: Careful combinations

Most reports about HIV medicines in development usually centre on their effectiveness—how well they can suppress HIV and lead to improvement in the immune system.

B. Super pills — the treatments of the future?

When potent combination therapy for HIV/AIDS became available in the mid-to-late 1990s, people with HIV/AIDS (PHAs) had to take a handful of pills according to a strict schedule, sometimes as often as three times daily. A decade later, many therapies can be taken twice or even once daily, usually with fewer pills than before. But there is no potent daily anti-HIV regimen that is available in just one pill.

 TreatmentUpdate 155: April / May - Vol. 18, No. 2

English  Françias

 TreatmentUpdate 154: January / February - Vol. 18, No. 1

EnglishFrançias  

---

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980,2006. AEGiS . All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.